Edwards Lifesciences (EW): analysis in plain words
Is Edwards Lifesciences cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Edwards Lifesciences (EW) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Edwards Lifesciences according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Edwards Lifesciences (EW) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $99.37 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 59.1x | Price over earnings per share |
| Revenue growth | +13.6% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 15.4% | Profit for every 100 of sales |
| Net debt / EBITDA | Net cash (more cash than debt) | Years of operating profit to repay debt |
| Dividend yield | 0.00% | Annual dividend over price |
| Market cap | $57.3 billion | What the stock market values it at |
The Edwards Lifesciences figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any EW figure that is not available shows as N/A: we do not estimate it.
How Edwards Lifesciences makes money
Edwards Lifesciences makes artificial heart valves. Its biggest business is transcatheter aortic valve replacement, or TAVR, with the Sapien family, and it also sells mitral and tricuspid repair and replacement devices such as Pascal and Evoque, plus surgical valves. Hospitals in the United States, Europe and Japan are its main customers.
Over the last 12 months, Edwards Lifesciences brought in revenue of $6.5 billion. For every 100 it sells, Edwards Lifesciences keeps 77.8 after the direct cost of what it sells (gross margin) and 29.8 after all operating costs (operating margin).
Edwards Lifesciences against its sector
To know whether a Edwards Lifesciences figure is high or low you have to put it next to similar companies. This table compares Edwards Lifesciences with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Edwards Lifesciences | healthcare and pharma median |
|---|---|---|
| P/E | 59.1x | 31.3x (30) |
| Revenue growth | +13.6% | +8.3% (33) |
| Net margin | 15.4% | 14.9% (33) |
| Dividend yield | 0.00% | 1.52% (33) |
| Net debt / EBITDA | -1.8x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Edwards Lifesciences trades on a higher P/E, grows faster and pays a lower dividend yield. By size, Edwards Lifesciences ranks number 25 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Edwards Lifesciences
What works in favour of Edwards Lifesciences, according to its figures as of November 4, 2026:
- Analysts expect Edwards Lifesciences earnings to rise: its P/E on the next 12 months of estimated earnings is 29.4x, below the current 59.1x.
- Edwards Lifesciences holds more cash than debt (net cash), so it does not depend on lenders to keep investing and is better placed to ride out a bad year.
The main risk for Edwards Lifesciences
The price already assumes a lot: Edwards Lifesciences trades at 59.1x its last 12 months of earnings, against 31.3x for the healthcare and pharma median. If growth disappoints, the multiple can shrink and the share price with it.
And, like the rest of healthcare and pharma, Edwards Lifesciences is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Edwards Lifesciences
Is it a good time to buy Edwards Lifesciences stock?
Fintols does not tell you whether to buy or sell Edwards Lifesciences, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Edwards Lifesciences stock trades at $99.37, 1% below its 52-week high ($100.25) and 33% above its low ($74.66). Its P/E is 59.1x against a healthcare and pharma median of 31.3x, and 29.4x on the earnings analysts expect over the next 12 months. With Edwards Lifesciences, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Edwards Lifesciences pay a dividend?
No. As of November 4, 2026, Edwards Lifesciences does not pay a dividend: what it earns stays in the company to grow, invest or, where it does so, buy back shares. Anyone buying Edwards Lifesciences today is counting on the share price rising, not on income.
Is Edwards Lifesciences stock expensive?
It depends on what you compare it with. On P/E, Edwards Lifesciences trades at 59.1x its last 12 months of earnings: more expensive than the healthcare and pharma median (31.3x). A high P/E alone does not make Edwards Lifesciences expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Edwards Lifesciences's competitors?
On Fintols we compare Edwards Lifesciences with Humana, Moderna and Dexcom, which are also in healthcare and pharma. As of November 4, 2026, Humana is worth $50.1 billion and trades on a P/E of 39.5; Moderna is worth $103.2 billion; Dexcom is worth $33.0 billion and trades on a P/E of 34.8. Each has a side-by-side comparison with Edwards Lifesciences below.
Edwards Lifesciences competitors
- Humana (HUM) analysis · Edwards Lifesciences vs Humana comparison
- Moderna (MRNA) analysis · Edwards Lifesciences vs Moderna comparison
- Dexcom (DXCM) analysis · Edwards Lifesciences vs Dexcom comparison
To understand Edwards Lifesciences better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Edwards Lifesciences: healthcare and pharma stocks and S&P 500 companies. Open the full EW analysis with its valuation and scenarios. Educational content about Edwards Lifesciences, not investment advice.